Biotek-snakken — Juli 2022
-
Xbrane Biopharma Q2’22: Xlucane
Launch Anticipated to Q1’23
Research Note Friday July 22
Redeye comments on Xbrane Biopharma’s Q2 2022 report, which despite the recent setback, leaves us feeling encouraged ahead of the European launch of Xlucane, anticipated in Q1 2023. https://www.redeye.se/research/849301/xbrane-biopharma-q222-xlucane-launch-anticipated-to-q123?utm_source=note&utm_medium=email -
Især bemærkningen om evt adgang til finansiering gennem non-dilutive finansiering ser godt ud
With SEK 250m cash on the balance sheet at the end of the second quarter, there should be no financing need in the coming twelve months. With current prospects, the company has financial flexibility and could likely access non-dilutive financing as options if required
. -
What's the best stock to buy right now? Our healthcare roundtable nominates our three favorites https://www.proinvestor.com/investornyt/854766/2022-roundtable-our-favorite-picks-right-now
-
Exitnu er du i Bioporto? Denne gang tror jeg fuldt og fast på, at der kommer en godkendelse. De har ansat de rigtige mennesker og har haft en lang og løbende dialog med FDA. Jeg har selv en stor portion aktier i selskabet, og er overbevist om, at der vil tændes en raket, når godkendelsen kommer. Vil vi så se en kurs på +10?
-
Cantargia reports new positive preclinical efficacy data for CAN10 supporting development in myocarditis
https://www.proinvestor.com/boards/104710 -
-
@fandel .hvis en godkendelse kommer kan vi godt regne med kurs over 100 på bioporto over lidt tid
måske lemminge effekt fra bava smitter lidt af på aktien det var danskerne der købte ind igår -
7 Undervalued Biotech Stocks to Buy Before They Boom
While medical innovations offer tremendous appeal, investors can still get a discount in this sector via undervalued biotech stocks to buy.
InvestorPlace (investorplace.com)
-
@Sukkeralf: Ja dejligt at der endelig kommer data. Det er vel disse data, som skal sammenlignes med (Enhertu dose expansion): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292921/
-
Ja det må være oplagt at sammenligne med Enhertu fase I data - håber at de ved at ændre kohorter, har fået bedre styr på bivirkningsprofilen for ZW49. Nogle analytikere har på det seneste spurgt ind til om vi skal forvente et nyt ADC baseret på zanidatamab og Zymes nye TOPO-1 inhibitor. Sutro sadler også lidt om og satser på på TOPO-1 inhibitorer.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind